Ozempic (semaglutide) is FDA-approved to treat type 2 diabetes and to reduce the risk of major cardiac events and chronic kidney disease in certain populations
Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
Genetic Testing Guides Personalized Semaglutide Response Individual response to semaglutide varies significantly based on genetic predispositions affecting GLP-1 receptor sensitivity and metabolism
Menstrual cycle phase, contraceptive use, and menopause stage may warrant dosing adjustments
The integrated cooling mechanism Sofcool protects the uppermost skin layer from burning